We are live on ! Find out more
DCMIC

Decheng Capital Management III (Cayman) Portfolio holdings

AUM $300M
1-Year Est. Return 15.74%
This Fund
S&P 500
This Quarter Est. Return
+3.72%
1 Year Est. Return
+15.74%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$248M
AUM Growth
-$19.3M
Cap. Flow
-$17.3M
Cap. Flow %
-6.97%
Top 10 Hldgs %
83.16%
Holding
28
New
2
Increased
1
Reduced
1
Closed
4

Top Buys

Rank Stock Value
1
BYSI icon
BeyondSpring
BYSI
+$9.6M
2
ARGX icon
argenx
ARGX
+$8.11M
3
ATRC icon
AtriCure
ATRC
+$1.92M

Top Sells

Rank Stock Value
1
ALBO
Albireo Pharma Inc
ALBO
+$13.5M
2
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
+$11.5M
3
NAUT icon
Nautilus Biotechnolgy
NAUT
+$540K

Sector Composition

Rank Sector Weight
1 Healthcare 79.11%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALBO
26
DELISTED
Albireo Pharma Inc
ALBO
– –
-623,342
Closed -$13.5M
1
2

Similar funds

IBT
International Biotechnology Trust London, United Kingdom $297M AUM 17.25% 1-Year Est. Return
3LCM
3D/L Capital Management Hartford, Connecticut $308M AUM 13.67% 1-Year Est. Return
DT
Daniels + Tansey Wilmington, Delaware $289M AUM 18.06% 1-Year Est. Return
SFG
Steward Financial Group Colleyville, Texas $315M AUM 13.78% 1-Year Est. Return
TFA
Triad Financial Advisors Greensboro, North Carolina $284M AUM 14.95% 1-Year Est. Return
AEPLI
AH Equity Partners LSV I Menlo Park, California $315M AUM 9.31% 1-Year Est. Return
CC
Chanos & Company New York $318M AUM 4.62% 1-Year Est. Return
KBC
Key Bridge Compliance $319M AUM

Decheng Capital Management III (Cayman)'s Q1 2023 Portfolio in Review

As of Q1 2023, Decheng Capital Management III (Cayman) held 28 positions worth $248M, down 7.2% from $267M the previous quarter. Its ten largest holdings account for 83% of the portfolio.

Decheng Capital Management III (Cayman) withdrew a net $17.3M in Q1 2023, closing 4 positions and reducing 1 holding. Its most notable exit was Albireo Pharma Inc, an estimated $13.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 79% of assets, up from 77% a quarter earlier.

Against the trend, Decheng Capital Management III (Cayman) opened a new position in BeyondSpring worth $5.55M.

  • Decheng Capital Management III (Cayman)'s largest Q1 2023 buy was BeyondSpring: 4,958,143 shares worth $5.55M.
  • Decheng Capital Management III (Cayman) added most to argenx in Q1 2023, an estimated $8.11M increase.
  • Decheng Capital Management III (Cayman)'s biggest Q1 2023 reduction was Prometheus Biosciences, Inc. Common Stock, cutting an estimated $11.5M.
  • Decheng Capital Management III (Cayman) fully exited Albireo Pharma Inc in Q1 2023, selling an estimated $13.5M.
  • Decheng Capital Management III (Cayman)'s ten largest holdings make up 83% of its $248M portfolio in Q1 2023.
  • Decheng Capital Management III (Cayman) opened 2 new positions and closed 4 in Q1 2023.
  • Decheng Capital Management III (Cayman)'s portfolio value fell 7.2% quarter-over-quarter to $248M.

Based on Decheng Capital Management III (Cayman)'s 13F filing for Q1 2023, filed 10 May 2023.